MTW Research and Development

17/12/2022

Interested in a role within our team, then get in touch!

20/05/2022

Your final fact of the week as we celebrate Clinicsl Trials Day today. 😎

The MTW Ophthalmology Team took part in a clinical trial of a new drug for Retinal Vein Occlusion called Faricimab. Shortly after recruitment finished, Faricimab was approved for use by the US Food and Drug administration for Diabetic Macula Oedema and Wet Age-Related Macular Degeneration. 🌟

20/05/2022

Happy International Clinical Trials Day 2022! 🎉

We would like to celebrate and thank all of our clinicians and MTW's Research and Innovation team, made-up of governance staff, clinical trial co-ordinators, finance staff, nurses, practitioners, physiotherapists, radiographers and midwives. 🌟

We would also like to thank our Patient Research Ambassadors for all of their time and amazing work, please find further information on the role of a PRA below! 👇🏽

Thank you for supporting research - because of your dedication, we are able to help change the future of our patients. 💙

19/05/2022

In the build-up to International Clinical Trials Day tomorrow. we are celebrating all week and will be posting incredible facts from our Research Team everyday this week! 💙

MTW opened both ‘REMAP-CAP’ and the ‘GenOMICC’ study where both trials were required to recruit patients with a chest infection or an emerging chest infection. These studies were opened pre-pandemic; this meant that the Intensive Care Team were able to recruit some of the first patients admitted for COVID-19 to a trial, thereby offering the patients novel treatments where there was no standard of care available yet. 🏥

18/05/2022

In the build-up to International Clinical Trials Day this Friday 20 May, we are celebrating all week and will be posting incredible facts from our Research Team everyday this week! 🏥

MTW Radiotherapy Team have been recruiting to ‘PACE-C’, a randomised Prostate Cancer Trial, looking to establish the whether 5 treatments of trial radiotherapy demonstrates the equivalent clinical outcome as 20 standard of care treatments. 💙

17/05/2022

In the build-up to International Clinical Trials Day this Friday 20 May, we are celebrating all week and will be posting incredible facts from our Research Team everyday this week! 🏥

The MTW Oncology Breast Team are currently the number 1 recruiter in the world for the PALMIRA study. This trial is looking at different ways of treating advanced breast cancer that cannot be treated with surgery or radiation therapy. The trial focuses on patients that have been previously treated with a drug called Palbociclib as well as an endocrine therapy. Within this trial, the patients will be treated with Palbociclib, and potentially another endocrine therapy, or with just endocrine therapy alone. 💙

16/05/2022

In the build-up to International Clinical Trials Day this Friday 20 May, we are celebrating all week and will be posting incredible facts from our Research Team everyday this week! 🎉

Today’s focus is on our Sexual Health Research Team who worked on the PrEP trial. 💙

The MTW Sexual Health Research Team were part of the PrEP study, which provided prophylactic treatment for people infected with HIV, with the trial conducted both at the acute and community clinics simultaneously. 🏥

The study was such a success that the government has now implemented the study pathway as an ongoing treatment pathway for this group of patients. 🙌🏾

04/02/2022

Today is

Our Oncology research team have been working hard on our cancer research this year, still providing an opportunity to take part in research throughout the pandemic.

The Oncology research team work in studies across a huge range of specialities, including; Breast, Haematology, Lung, Melanoma, Gynaecology, Urology, Colorectal and Upper GI cancers.

Thank you to all those who have participated in research this year ❤️

03/01/2022

January is .

Here at Maidstone and Tunbridge Wells NHS Trust we participate in the Non-alcoholic Fatty Liver Disease (NAFLD) BioResource, which is part of the NIHR BioResource.

This study aims to understand the genetics and natural history of NAFLD, and investigate the impact of co-morbidities. It is hoped that this study will also help develop a centralised national recallable BioResource of NAFLD patients to support scientific and clinical NAFLD research in the future. This includes collecting and storing blood as well as clinical and lifestyle data, and creating a bank of recallable volunteers to help with further research.

We want to thank all participants for their contributions to this important study 😊

25/12/2021

🎄MERRY CHRISTMAS🎄

Thank you to all the participants who took part in research studies this year, and to all the staff that made it possible!

We're looking forward to what we can achieve next year with your help 🌟

03/12/2021

Today is

We want to take this opportunity to thank all volunteers involved in research, and in particular our Patient Research Ambassadors who provide vital support to help run research at Maidstone and Tunbridge Wells NHS Trust.

Thank you all so much ❤️

04/10/2021

NIHR Kent, Surrey and Sussex is supporting the PRINCIPLE trial, which is vital in trying to find effective treatment against COVID-19.

If you have a positive test, and have been experiencing COVID-19 symptoms and want further information, follow the link below 👇👇👇

Become a hero from home!

Oxford University’s PRINCIPLE trial is looking for safe and effective COVID-19 treatments that can help people recover more quickly.

If you have a positive test and have been experiencing COVID-19 symptoms recently then please visit www.principletrial.org